Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Merck & Co., Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
MRK
New York
2834
www.merck.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Merck & Co., Inc.
US pharma giant Merck backs healthcare marketplace HD in Southeast Asia
- Feb 13th, 2025 2:00 am
Why Merck & Co., Inc. (MRK) is Declining
- Feb 12th, 2025 6:27 pm
Jim Cramer on Merck & Co., Inc. (MRK): ‘Drug Stocks Are Really Getting Hurt’
- Feb 11th, 2025 3:42 pm
Health Canada Approves Merck's KEYTRUDA® (pembrolizumab) for the treatment of adult patients with resectable Stage II, IIIA, or IIIB (T3-4N2) non-small cell lung carcinoma (NSCLC) in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery
- Feb 11th, 2025 12:00 pm
In the crowded cardio space, it’s David vs. Goliath for small biotechs
- Feb 11th, 2025 7:27 am
Merck (MRK) Downgraded by TD Cowen Over Keytruda, Gardasil Concerns
- Feb 10th, 2025 11:02 pm
TD Cowen cuts Merck stock to hold on uncertainty around Keytruda, Gardasil
- Feb 10th, 2025 2:04 pm
Douglas Baker Bought 1,500% More Shares In Merck
- Feb 10th, 2025 11:05 am
Merck & Co. (MRK): ‘Forget It… It’s China,’ Jim Cramer on Vaccine Rollout Woes
- Feb 9th, 2025 8:03 pm
Is Merck & Co., Inc. (MRK) the Best Dividend Stock According to Wall Street Analysts?
- Feb 8th, 2025 10:34 am
Merck Full Year 2024 Earnings: EPS Misses Expectations
- Feb 7th, 2025 7:20 pm
Earnings Update: Merck & Co., Inc. (NYSE:MRK) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
- Feb 6th, 2025 7:08 pm
Merck Announces Phase 3 waveLINE-010 Trial Initiation Evaluating Zilovertamab Vedotin, an Investigational Antibody-Drug Conjugate, for the Treatment of Patients With Previously Untreated Diffuse Large B-Cell Lymphoma
- Feb 6th, 2025 11:45 am
With uncertainty roiling Big Pharma, execs are placing lower-risk bets
- Feb 6th, 2025 10:07 am
Is Merck & Co. (MRK) the Best Dividend Stock to Buy and Hold?
- Feb 5th, 2025 10:10 pm
Analysts Defend Merck Amid Investor Concerns Over Weak Guidance
- Feb 5th, 2025 6:25 pm
Evaxion Biotech price target lowered to $6 from $35 at Lake Street
- Feb 5th, 2025 1:45 pm
Why Merck & Co. Inc. (MRK) Went Down on Tuesday
- Feb 5th, 2025 1:06 pm
Merck Is Suffering From a Classic Pharma Problem
- Feb 5th, 2025 12:00 pm
Big Pharma is staying quiet on Trump's China tariffs
- Feb 5th, 2025 11:39 am
Scroll